Nouscom Raises $135M to Advance Cancer Interception

Oncology medicine spent seventy years attacking established tumors after malignant cells spread across human organs. Traditional cancer therapies: surgical excision, radiation bombardment, and toxic chemotherapy infusions: attempt to eradicate cancerous tissue after abnormal growths become visible on radiological scans. By that point, cancer cells have accumulated complex genetic mutations, suppressed regional immune responses, and established vascular networks that resist treatment. Clinical-stage biotechnology company Nouscom is attempting to shift medicine from reactive cancer treatment to proactive cancer interception. On Monday, October 19, 2026, the Basel-headquartered company announced the closing of an oversubscribed €120M ($135M) Series D financing round. Co-led by M Ventures, the corporate venture arm of Merck KGaA, and Revelation Partners, the financing funds a registration-enabling clinical trial for NOUS-209, an off-the-shelf neoantigen immunotherapy engineered to prevent colorectal and related tumors in high-risk genetic carriers. The massive capital commitment arrives as institutional investors redirect funds toward preventative therapeutics, an investment trend aligned with funding patterns we tracked when Senticell secured seed funding for liquid biopsy diagnostics.

The Series D round drew broad participation from international life sciences investors, including Angelini Industries, the European Investment Bank through its Aurea co-investment facility, and Neva SGR. Returning backers 5AM Ventures, Andera Partners, Bpifrance, EQT Life Sciences, and Versant Ventures participated fully, reflecting strong investor conviction in clinical data released this week. Proceeds will advance NOUS-209 through a single, global, registration-enabling trial aimed at securing commercial market approval for cancer interception in Lynch Syndrome carriers. Lynch Syndrome is an inherited genetic condition affecting millions worldwide, leaving carriers with an eighty percent lifetime risk of developing colorectal, endometrial, and other aggressive gastrointestinal cancers. Under the leadership of chief executive officer Marina Udier, Nouscom is seeking to prove that training the human immune system to recognize shared genetic errors can halt cancer before malignant tumors materialize. The convergence of genetic science and computational immunotherapy mirrors research we explored when tech titans backed large-scale virtual cell models.

The Genetic Tragedy of Lynch Syndrome and DNA Mismatch Repair

To grasp why institutional investors committed $135M to Nouscom, one must inspect the genetic mechanics of Lynch Syndrome. Lynch Syndrome is caused by inherited germline mutations in DNA mismatch repair genes, including MLH1, MSH2, MSH6, and PMS2. In healthy human bodies, these mismatch repair proteins act as proofreaders, repairing microscopic copying errors that occur when cells duplicate genetic material.

In individuals carrying Lynch Syndrome mutations, this cellular proofreading apparatus fails. When intestinal cells divide, uncorrected errors accumulate in repetitive DNA sequences called microsatellites, leading to microsatellite instability. These errors trigger frameshift mutations, causing cells to produce abnormal, truncated proteins called frameshift peptides. Over decades, these mutant cells multiply, transforming into precancerous adenomatous polyps and eventually invasive malignant tumors. Currently, individuals diagnosed with Lynch Syndrome live under constant medical surveillance. Standard care requires invasive colonoscopies every twelve months, coupled with prophylactic surgeries to remove healthy ovaries, fallopian tubes, and uterine tissue to avert cancer onset. No pharmacological or immunotherapeutic treatment exists to intercept cancer formation. The emotional burden of genetic screening reflects themes we documented when specialized medical manufacturing platforms secured growth capital.

The Molecular Architecture of the NOUS-209 Off-the-Shelf Vaccine

The core scientific breakthrough behind NOUS-209 is its off-the-shelf neoantigen design. Over the past five years, prominent biotechnology companies like Moderna and BioNTech pursued personalized cancer vaccines. Those personalized therapies require doctors to biopsy an existing tumor, sequence its individual mutations, synthesize custom messenger RNA strands, and formulate a unique vaccine for that single patient. That personalized process takes two to three months, costs over $100,000 per patient, and can only occur after a tumor exists.

Nouscom discovered that mismatch repair deficient cancers do not produce random mutations. Because DNA copying machinery slips at predictable microsatellite sequences, different Lynch Syndrome patients produce identical frameshift peptides. Nouscom mapped these shared mutations, creating an off-the-shelf vaccine that encodes 209 distinct frameshift neoantigens shared across microsatellite-unstable tumors. The therapy utilizes a heterologous prime-boost viral vector platform. A great ape adenovirus vector delivers the genetic payload during the initial priming dose, followed by booster doses delivered via a modified vaccinia Ankara vector. Because the human immune system has never encountered this specific animal adenovirus, it does not neutralize the vector before the genetic instructions enter cells. The vaccine instructs human muscle tissue to express all 209 neoantigens, prompting bone marrow to generate an army of cytotoxic T-cells trained to patrol the digestive tract. The minute a pre-cancerous polyp expresses any of those 209 mutant proteins, circulating T-cells spot the anomaly and destroy the cells immediately. The structural engineering of targeted biological agents matches laboratory protocols we explored when research teams established physical biological test environments.

Two-Year Clinical Data Presented at the ESMO Congress

The timing of the Series D round coincided with the release of long-term Phase 1b/2 clinical trial results presented at the European Society of Medical Oncology Congress in Madrid. Study principal investigator Dr. Eduardo Vilar-Sanchez, chair ad interim of Clinical Cancer Prevention at The University of Texas MD Anderson Cancer Center, unveiled two-year interception metrics that astonished attending oncologists.

According to the official study abstract, all evaluable Lynch Syndrome carriers who received NOUS-209 remained completely free of advanced adenomatous polyps and colorectal cancer, as verified by independent colonoscopic examinations at both year one and year two of follow-up. In a patient cohort with an eighty percent lifetime risk of aggressive malignancies, recording zero colorectal cancers across forty-three patients at year one and seventeen patients at year two represents an unprecedented clinical signal. Blood assays confirmed that the vaccine generated broad, potent, and durable neoantigen-specific CD8+ and CD4+ T-cell responses that persisted for months, with immune responses strengthening after annual booster doses. The treatment was well tolerated, producing only mild, transient injection-site soreness and low-grade fatigue. These results validated the hypothesis that the human immune system can be trained to eradicate premalignant lesions long before they threaten human life. Verification testing standards across advanced biological tools were examined in our review of Scopia Surgical securing capital for robotic navigation.